| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5fc5aa973a8264c38a2c8cc553853a42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ae344bf33fb1d5b05491d359254538d3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb5ec370cea824676bc3a9c41701e773
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a39832d4e6180c19ec041763ace06d0f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8fa39ab41c5f69f0b1d1921c99f244ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5cf811e10ad9068ddf72c04b69c8ba8 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2009-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40e17707f3599ddb3826152f19e1577b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99b65892783a5f723fabfc64a7e6f043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27455abc8d407c8fed75aa68b1f64898 |
| publicationDate |
2009-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2009103160-A1 |
| titleOfInvention |
Treatment and prevention of dry age-related macular degeneration by activating cd36 |
| abstract |
The present invention relates to methods and compositions for the prevention and/or treatment of dry age-related macular degeneration by administering a CD 36 -activator compound to a subject in need thereof; wherein the CD36 activator compound is the CD36 antibody FA6-152, or the growth hormone (GH)-releasing peptide family-derived compound EP80317 or the compound of Formula 1[ A-(Xaa) a -N(R A )-N(R B )-C(O)-(Xaa') b -B]; and wherein the activator compound acts to maintain a healthy choroid and retinal oxygenation by enhanced COX2 expression. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014033130-A1 |
| priorityDate |
2008-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |